

Advancing the Frontier: A Comprehensive Review of Emerging Therapeutic Strategies for Amyotrophic Lateral Sclerosis with a Focus on Disease Reversal Potential

I. Executive Summary

Amyotrophic Lateral Sclerosis (ALS) represents a formidable challenge in neurology, characterized by progressive motor neuron degeneration leading to paralysis and premature death. Current FDA-approved treatments offer only modest benefits, primarily slowing disease progression rather than halting or reversing its devastating course. This report critically examines both established and emerging therapeutic strategies for ALS, with a particular emphasis on their potential to achieve disease reversal. A significant shift in the therapeutic paradigm is observed, moving from broad neuroprotective approaches to highly targeted interventions, especially those addressing specific genetic mutations. The endocannabinoid system and cell-based therapies are also emerging as multifaceted therapeutic hubs, offering neuroprotection and immunomodulation. While true disease reversal remains largely an aspirational goal for most therapies, recent clinical data for Qalsody in SOD1-ALS patients presents compelling evidence of functional stabilization and even improvement, setting a new benchmark for therapeutic efficacy. The analysis underscores the critical importance of early intervention, precision medicine, and the development of robust biomarkers to unlock the full potential of these novel treatments.

II. Introduction: The Unmet Need in Amyotrophic Lateral Sclerosis (ALS)

ALS: A Complex Neurodegenerative Disorder and its Heterogeneous Nature

Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease, is a relentlessly progressive and ultimately fatal neurodegenerative disorder. It is defined by the selective degeneration of upper and lower motor neurons in the brain, brainstem, and spinal cord. This neuronal loss leads to progressive muscle weakness, atrophy, paralysis, and culminates in respiratory failure, typically resulting in death within 2 to 5 years of symptom onset.¹

The pathology of ALS is notably heterogeneous, manifesting as both familial (fALS), accounting for approximately 10% of cases, and sporadic (sALS), which comprises the vast majority at around 90%.¹ Genetic research has identified over 20 genes linked to ALS, with mutations in

SOD1, *C9orf72*, *FUS*, and *TARDBP* being among the most common genetic drivers in both familial and, to a lesser extent, sporadic forms.¹ Beyond the direct loss of motor neurons, the disease pathophysiology is complex and multifactorial, involving a detrimental interplay of axonal dysfunction, chronic oxidative stress, mitochondrial dysfunction, and the aggregation of misfolded proteins within affected cells.¹ Furthermore, ALS is increasingly recognized as extending beyond a purely motor disorder, with a significant proportion of patients (15-50%) experiencing cognitive disturbances, including frontotemporal lobar dementia (FTLD), indicating broader central nervous system involvement.²

Current FDA-Approved Treatments and Their Limitations

Despite extensive research, the therapeutic landscape for ALS remains limited. Currently, only a handful of drugs have received FDA approval: Riluzole (marketed as Rilutek, Tiglutik, and Exservan), Edaravone (Radicava), and Tofersen (Qalsody).²

Riluzole, the first FDA-approved drug in 1995, functions as a glutamate release inhibitor. While it offers a modest survival advantage, typically prolonging life by approximately 2-3 months in clinical trials, real-world evidence suggests a potentially broader benefit ranging from 6 to 19 months.⁷

Edaravone, approved in 2017, is an antioxidant believed to mitigate oxidative stress. Clinical trials demonstrated a reduction in the rate of disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R).⁶ These medications primarily aim to slow the inexorable progression of the disease or manage its debilitating symptoms. However, they do not offer a cure or lead to significant functional recovery, highlighting the profound unmet need in ALS treatment.²

The Critical Pursuit of Disease-Modifying and Reversal Therapies

The marginal efficacy of existing treatments underscores an urgent imperative for the development of novel therapies capable of fundamentally altering the disease trajectory. The ultimate goal in ALS research is to identify interventions that can not only significantly slow progression but, ideally, achieve disease reversal or substantial functional recovery.² Contemporary research efforts are increasingly concentrated on elucidating the intricate genetic and molecular mechanisms underlying ALS pathogenesis. This deeper understanding is paving the way for the development of highly targeted therapeutic approaches designed to address the root causes of neurodegeneration, moving beyond symptomatic management.¹

A notable trend in ALS drug development is the evolution from broadly acting neuroprotective agents, such as

Riluzole and Edaravone, to precision therapies that directly target specific genetic mutations. This progression reflects a growing comprehension of ALS's diverse genetic underpinnings and a strategic pivot towards personalized medicine. The implication is that future breakthroughs are more likely to arise from interventions that precisely address identified pathological pathways, rather than general neuroprotective strategies.

Another critical area of focus is neuroinflammation, which is consistently recognized as a central driver across various neurodegenerative conditions, including ALS. However, the role of neuroinflammation is nuanced and complex, presenting both therapeutic challenges and opportunities. For instance, microglia, key immune cells in the central nervous system, exhibit a dual role: they can be beneficial in the early stages of ALS by clearing debris and promoting repair, but become neurotoxic when chronically overactivated and adopting a pro-inflammatory phenotype in later stages.¹⁴ This understanding suggests that simply suppressing inflammation may not be sufficient, and could even be detrimental if not precisely modulated. The challenge lies in developing therapies that can fine-tune the inflammatory response, promoting beneficial microglial phenotypes (e.g., M2 anti-inflammatory) while inhibiting detrimental ones (e.g., M1 pro-inflammatory).¹⁵ This nuanced approach to immunomodulation is anticipated to be a cornerstone of future successful treatments.

III. Treatments with Exceptional Promise from Initial Research Material

A. Genetic Therapies: Targeting the Root Cause

Genetic therapies represent a frontier in ALS treatment, aiming to address the fundamental molecular defects that drive the disease.

CRISPR/Cas9-Mediated Gene Correction

CRISPR/Cas9 technology has emerged as a powerful tool for investigating ALS pathophysiology and holds significant therapeutic potential. This gene-editing system is being utilized to correct common mutations in patient-derived induced pluripotent stem cells (iPSCs) and animal models, providing invaluable insights into disease mechanisms and potential therapeutic avenues.¹

The application of CRISPR/Cas9 allows researchers to directly verify the pathological effects of ALS-associated mutations by comparing the phenotypes of mutated cells with their gene-corrected, isogenic counterparts.¹ For instance, in models of

SOD1 mutations (e.g., A272C, E100G, L144FVX), gene correction in iPSCs has successfully reversed various

pathological phenotypes. These reversals include normalization of altered gene expression, an increase in motor neuron proportion and soma size, extended neurite length, and a reduction in cell death.¹ Critically,

in vivo genome editing in hSOD1 G93A transgenic mouse models has demonstrated a reduction in mutant SOD1 protein expression, an increase in motor neuron count, improved motor function, reduced muscle atrophy, delayed disease onset, and, notably, increased survival.¹

Beyond SOD1, CRISPR/Cas9 has been applied to other major genetic forms of ALS. For the **C9orf72 repeat expansion**, this technology has been used to excise the problematic hexanucleotide repeat, leading to a decrease in RNA foci formation, reduced methylation, and a rescue of AMPA-induced excitotoxicity in iPSC-derived neurons.¹ In the context of

FUS mutations, gene correction has successfully rescued mitochondrial transport defects and normalized cytoplasmic FUS localization.¹ Furthermore, for

TARDBP mutations, correcting the M337V mutation significantly increased brain-derived neurotrophic factor (BDNF) secretion in neurons, highlighting a direct link between the mutation and a critical neurotrophic pathway.¹

CRISPR/Cas9-mediated gene correction demonstrates significant promise for advancing the understanding of ALS and holds considerable potential for disease modification and even reversal in preclinical models. The ability to reverse pathological phenotypes, delay disease onset, and increase survival in animal models provides compelling evidence of its capacity to address the fundamental mechanisms of the disease.¹ However, current limitations include potential off-target effects and the relatively low efficiency of gene correction via homology-directed repair pathways (typically less than 1%).¹ Overcoming these technical hurdles is crucial for its translation to clinical applications.

Antisense Oligonucleotides (ASOs) - Qalsody (Tofersen)

Antisense oligonucleotides (ASOs) represent another powerful genetic therapeutic approach, exemplified by Qalsody (tofersen). Qalsody is an ASO designed to specifically bind to messenger RNA (mRNA) transcribed from the *SOD1* gene, thereby reducing the production of the toxic SOD1 protein. This targeted therapy received FDA approval in 2023 for the treatment of ALS associated with *SOD1* mutations.⁷

While the Phase 3 clinical trial for Qalsody did not meet its primary functional endpoint, its approval was based on a significant reduction in neurofilament light chain (NfL) levels, a recognized blood-based biomarker for neurodegeneration.⁸ Subsequent real-world data from patients treated with Qalsody have shown "robust and sustained declines" in NfL levels, which are strongly associated with a slowing of ALS progression.¹⁷ More importantly, these real-world observations indicate that Qalsody treatment not only helps stabilize ALS but also leads to "meaningful preservation of function and suggestions of sustained improvement in neurologic function in some patients." Some reports even suggest the "potential not only to stabilize the disease but also to restore lost function".¹⁷

Qalsody demonstrates high potential for disease modification and functional recovery, particularly within the specific population of SOD1-ALS patients. The observed stabilization and, in some cases, actual improvement in

function, coupled with the normalization of a key biomarker, represent a significant breakthrough beyond merely slowing the rate of decline. This evidence stands as the most compelling indication of disease reversal observed in human ALS patients among the currently available clinical data.¹⁷

B. Cannabinoid System Modulators: Neuroprotection and Anti-Inflammation

The endocannabinoid system (ECS) and its various modulators are increasingly recognized for their multifaceted roles in neuroprotection and anti-inflammatory processes, making them attractive targets for ALS therapy.

Palmitoylethanolamide (PEA)

Palmitoylethanolamide (PEA) is an endogenous lipid mediator naturally produced by neurons and glial cells in the central nervous system (CNS) on demand in response to cellular stress or inflammation.¹⁵ It possesses a broad spectrum of neuroprotective, anti-inflammatory, and immunoregulatory properties.¹⁵

The therapeutic effects of PEA are primarily mediated through the activation of peroxisome proliferator-activated receptor- α (PPAR- α), alongside indirect modulation of cannabinoid receptors CB1 and CB2, and interactions with other novel targets such as GPR55 and TRPV1.²² PEA plays a crucial role in modulating microglial activation, specifically inhibiting the pro-inflammatory M1 polarization and potentially promoting the anti-inflammatory M2a phenotype.¹⁵ It also contributes to the stabilization of mast cells, which are significant contributors to neuroinflammation.¹⁹ Preclinical studies have consistently shown that PEA can reduce oxidative stress, dampen inflammatory responses, and promote neurogenesis.²⁴

In human studies related to ALS, PEA has shown some encouraging results. Clinical observations suggest its utility in ALS.²² Notably, treatment with PEA in a case of sporadic ALS led to an improved clinical picture, which was substantiated by electromyographic analysis and enhanced pulmonary function.²⁸ A larger cohort study involving 76 ALS patients treated with PEA demonstrated a slower decline in forced vital capacity (FVC) over time compared to untreated patients, indicating a beneficial effect on pulmonary function.²⁹ Furthermore, PEA was observed to reduce the desensitization of acetylcholine-evoked currents in microtransplanted muscle membranes from ALS patients, suggesting a positive impact on neuromuscular junction function.²⁹

PEA demonstrates moderate potential for disease modification or slowing progression in ALS, mainly attributed to its robust anti-inflammatory and neuroprotective mechanisms. While human data indicates symptomatic benefits and some positive impact on functional markers like pulmonary function²⁸, the evidence for significant disease reversal in humans is still in its nascent stages and necessitates extensive further investigation.²² Preclinical evidence, however, suggests that PEA may act as a disease-modifying agent, particularly if administered in the early stages of neurocognitive disorders.²⁵ The multi-target and highly redundant mechanisms through which PEA exerts its pro-homeostatic functions suggest a departure from the classical "one drug, one target, one disease"

pharmacological model, pointing towards a more fundamental modulation of the body's intrinsic responses to pathology.³¹

CB2 Receptor Agonists (e.g., AM-1241, CBN, WIN55212-2)

The cannabinoid receptor type 2 (CB2) plays a crucial role in immune regulation and its expression is often upregulated during inflammatory processes, including those seen in neurodegenerative diseases like ALS.³² In the spinal cords of G93A-SOD1 mutant transgenic mice, a widely used animal model for ALS, CB2 receptor mRNA and binding are selectively upregulated in a manner that parallels disease progression.³²

Preclinical studies investigating CB2 receptor agonists have yielded promising results:

- **Cannabinol (CBN)** was observed to delay the onset of symptoms in mice with experimentally induced ALS, although it did not significantly impact overall survival.³²
- **WIN55212-2**, another cannabinoid, demonstrated a delay in overall disease progression when administered to mice after the onset of ALS symptoms.³²
- Most notably, **AM-1241**, a specific CB2 agonist, when administered at symptom onset in the G93A-SOD1 mutant transgenic mouse model, significantly prolonged survival by 56%.³² This suggests that AM-1241 extended the period of motor neuron integrity and preserved function in these affected mice.³²
- Other cannabigerol (CBG) derivatives, such as VCE-003.2 and VCE-003, have also shown the ability to delay disease progression and reduce neuropathological signs in SOD1 mice.³⁴

Collectively, these preclinical findings indicate that the use of selective CB2 agonists, potentially combined with strategies to modulate CB1 receptors and enzymes that degrade endocannabinoids, can improve symptoms and increase survival in transgenic mouse models of ALS.³⁶

CB2 receptor agonists show moderate potential for disease modification or slowing progression based on robust preclinical evidence demonstrating delayed symptom onset, slowed disease progression, and significantly prolonged survival in animal models.³² While these results are highly encouraging, human clinical evidence specifically demonstrating disease modification or reversal with CB2 agonists in ALS is currently limited.³⁵ The endocannabinoid system, with its involvement in neurogenesis, neuroprotection, and regulation of various physiological processes, represents an intrinsic regulatory network. Modulating this system, whether by enhancing endogenous PEA or targeting CB2 receptors, aims to restore the body's own homeostatic mechanisms, which could lead to a more fundamental disease modification beyond mere symptom suppression.³³

IV. Expanding the Horizon: Other Emerging Treatments for ALS

Beyond the treatments identified from the initial research focus, a diverse array of other emerging therapies are

being explored for their potential to combat ALS. These approaches often target different facets of the complex disease pathology.

A. Cell-Based Therapies

Cell-based therapies offer a promising avenue for ALS treatment by aiming to replace or repair damaged cells and to create a supportive microenvironment for surviving motor neurons.

Stem Cell Therapy (Mesenchymal Stem Cells, Neural Stem Cells, Treg Cell Therapy)

Stem cell therapy for ALS is designed to either replenish lost cells or, more commonly, to provide a nurturing, neuroprotective microenvironment that can ameliorate detrimental conditions for diseased motor neurons, thereby slowing neurodegeneration.⁴

Mesenchymal Stem Cells (MSCs) are a particular focus due to their multi-faceted therapeutic properties. MSCs possess significant immunomodulatory capabilities, secreting anti-inflammatory cytokines and suppressing pro-inflammatory immune cells, which helps to reduce damaging neuroinflammation in ALS.⁶ Additionally, MSCs secrete a range of neurotrophic factors, including Vascular Endothelial Growth Factor (VEGF), Glial Cell Line-Derived Neurotrophic Factor (GDNF), and Brain-Derived Neurotrophic Factor (BDNF), which can protect motor neurons and support their survival.⁶ These cells also contribute to reducing oxidative stress and supporting mitochondrial function, both of which are critical in ALS pathogenesis.⁶ While there is some preliminary evidence suggesting MSCs may differentiate into neuron-like cells for direct cell replacement, this area requires much more research.⁶

Neural Stem Cells (NSCs), capable of differentiating into neuronal or glial cells, were initially considered for direct motor neuron replacement. However, the practical challenges of integrating transplanted neurons seamlessly into existing neural circuits and ensuring their survival within a diseased microenvironment have led to a shift in focus.⁴ The current "neighborhood theory" emphasizes the supportive role of NSCs in ameliorating detrimental conditions for diseased neurons.⁴ A Phase 1/2 study (STEMALS, NCT06344260) is currently evaluating the safety and efficacy of human neural stem cells (hNSCs) injected into the brain's lateral ventricles.⁴⁰

T Regulatory (Treg) Cell Therapy is another innovative cell-based approach, specifically targeting the inflammatory component of ALS. Umbilical cord blood-derived Treg cells are being investigated for their ability to resolve inflammation, which is central to many intractable illnesses, including ALS.⁴¹ These cells are "naturally wired to resolve inflammation" and offer logistical advantages as they can be manufactured at scale without requiring individual donor matching.⁴¹ COYA-302, a dual-mechanism biologic that combines low-dose IL-2 and CTLA4-Ig fusion protein to enhance Treg cell function, is preparing for Phase 2 testing in the second half of 2025. This therapy aims to suppress neuroinflammation and potentially slow or stabilize disease progression.⁴² RAPA-501

represents another T-cell therapy currently in Phase 2/3 testing.⁴²

Stem cell therapy remains a promising area of research, with encouraging preclinical studies providing the rationale for early-phase human clinical trials.⁴ Numerous trials are currently underway, exploring various stem cell types and delivery methods.⁴ Cell-based therapies, particularly those leveraging the immunomodulatory and neuroprotective properties of MSCs and Treg cells, show moderate potential for disease modification or slowing progression. While these therapies aim to protect existing neurons and potentially facilitate some replacement, definitive evidence of widespread functional recovery or reversal in humans is still under active investigation, and their overall efficacy in early trials remains to be fully elucidated.⁶

B. Novel Small Molecules and Biologics

Beyond cell-based approaches, a range of novel small molecules and biologics are being developed to target specific pathological pathways in ALS.

CNM-Au8 (Oral Suspension of Gold Nanocrystals)

CNM-Au8 is an oral suspension of clean-surfaced, catalytically active gold nanocrystals. Its proposed mechanism of action involves restoring nerve cell health and improving survival by enhancing neuronal metabolic energy production and utilization, and by reducing oxidative stress.⁴²

The RESCUE-ALS trial, a Phase 2 randomized, double-blind, placebo-controlled study of CNM-Au8 in early sporadic ALS, yielded significant findings. While the primary endpoint (change in summated motor unit index scores) was not statistically significant, pre-specified analyses in limb-onset participants showed a strong trend for reducing motor unit decline.⁴³ Notably, the study demonstrated a significant reduction in ALS disease progression, defined by a composite endpoint including death, tracheostomy, non-invasive ventilatory support, or gastrostomy tube placement, with a 37% absolute risk reduction.⁴³ Furthermore, CNM-Au8 treatment significantly reduced the proportion of participants experiencing a substantial decline in ALSFRS-R scores and improved quality of life.⁴³ These results suggest a meaningful impact on the disease course, and a larger study is currently underway to confirm its efficacy.⁴³

CNM-Au8 demonstrates moderate potential for disease modification or slowing progression. The Phase 2 data indicating a significant reduction in critical disease progression events and improved quality of life suggests a substantial impact on the overall trajectory of the disease.⁴³

Ibutilast (MN-166)

Ibudilast (MN-166) is a nonselective phosphodiesterase inhibitor with recognized neuroprotective properties, primarily acting by counteracting neuroinflammation. It modulates the survival and activation of immune cells within the central nervous system by inhibiting the production of pro-inflammatory agents from microglia.⁴⁴

Ibudilast is currently under investigation in a Phase 2b/3 clinical trial (COMBAT, NCT04057898) aimed at slowing ALS progression.⁴⁴ MediciNova, the developer, anticipates a Phase 2/3 trial readout in the coming year.⁴² Ibudilast shows moderate potential for disease modification or slowing progression by directly targeting neuroinflammation, a key pathological driver in ALS. Its advancement to a Phase 2b/3 trial indicates promising preclinical data and initial safety profiles, with ongoing evaluation of its efficacy in altering the disease course.

Other Notable Phase 2/3 Candidates (2023-2025)

The ALS therapeutic pipeline includes several other promising candidates in advanced clinical development (Phase 2 or 3) during 2023-2025:

- **SAR443820:** A Phase 2 randomized, double-blind, placebo-controlled study (NCT05237284) by Sanofi recently completed its primary phase in March 2024, with full study completion anticipated in January 2025. This trial aims to assess the efficacy, safety, tolerability, pharmacokinetics, and biomarker effects of SAR443820 in ALS patients.⁴⁵
- **TPN-101:** Transposon Therapeutics announced final results from its Phase 2 study for C9orf72-related ALS and/or frontotemporal dementia in July 2024.⁴⁷
- **AMX0114:** An investigational antisense oligonucleotide that targets the calcium-activated protease calpain-2, AMX0114 has received Fast Track designation from the FDA. Amylyx, the developer, is currently in Phase 1 testing, with early cohort data expected later this year.⁴²
- **Monepantel:** PharmAust Limited is in the process of designing a regimen for the inclusion of Monepantel in the HEALEY ALS Platform Trial.⁴⁷
- **MRG-001:** MedRegen LLC is planning an Open-Label, Single-Dose Study (NCT06315608) to assess the safety and pharmacodynamics of MRG-001, with an estimated start date of July 2025.⁴⁸
- **PTC857:** A Phase 2 study (NCT05349721) by PTC Therapeutics completed its primary phase in September 2024, with overall study completion expected in January 2025.⁴⁶

These diverse candidates represent emerging to moderate potential for disease modification in ALS, depending on their specific mechanisms of action and the outcomes of their ongoing or recently completed trials. Their advancement to Phase 2 and 3 trials signifies promising preclinical data and acceptable initial safety profiles, indicating a robust and active pipeline for future ALS therapies.⁴²

C. Neuromodulation Approaches

Neuromodulation techniques aim to alter neural activity to alleviate symptoms and potentially improve function in ALS.

Transcranial Magnetic Stimulation (TMS) and Spinal Direct Current Stimulation (sDCS)

These non-invasive neuromodulation techniques are being investigated for their ability to modulate neuronal excitability and improve motor function in ALS.

- **Transcranial Magnetic Stimulation (TMS)** provides a non-invasive method for assessing the functional integrity of the motor cortex and its corticospinal projections. Studies have revealed cortical hyperexcitability as an early characteristic in sporadic forms of ALS, often preceding clinical symptom onset.⁴⁹ Repetitive TMS (rTMS) has been explored for its potential beneficial effects on disease progression.⁴⁹ Preclinical research has shown increased survival in an ALS mouse model following non-invasive neuromodulation.⁵¹
- **Spinal Direct Current Stimulation (sDCS)** modulates motoneuron excitability, with preclinical evidence confirming induced changes in motoneuron excitability in SOD1 ALS mice.⁵² A pilot study investigated non-invasive transcutaneous spinal DC stimulation (tsDCS) to induce lasting excitability changes in lumbar spinal motor neurons, with the goal of impacting motor function loss and survival.⁵²

Current research in this area is active. PathMaker Neurosystems initiated a first-in-human trial for a non-invasive neuromodulation device in ALS in September 2023 and secured Department of Defense (DoD) funding for an ALS clinical trial in June 2024.⁵¹ Beyond direct motor function, Brain-Computer Interfaces (BCI) are also under development to enable patients to control assistive devices through thought alone, showing promise for enhancing communication and independence.⁴⁴

Neuromodulation approaches primarily offer symptomatic management, with emerging potential for functional improvement and slowing progression, rather than direct disease reversal. While some preclinical data suggest an increase in survival⁵¹, the primary impact observed in human applications from the available information is on modulating neuronal function and improving the overall quality of life for patients.⁴⁴

D. Neurotrophic Factors (Revisited)

Neurotrophic factors (NTFs) are proteins crucial for the development, survival, and maintenance of neurons. Impairment of NTFs has been consistently linked to the pathogenesis of ALS.⁵⁴

Challenges from Past Trials and New Insights

Despite their theoretical appeal, previous clinical trials utilizing NTFs for ALS treatment have largely failed to demonstrate significant efficacy.⁵⁴ The reasons for these failures are now better understood and are attributed to several critical factors:

- **Improper Administration Sites and Target Tissue:** Traditional delivery methods often targeted degenerating motor neurons within the brain or spinal cord. However, emerging data suggest that neuromuscular junctions (NMJs) and skeletal muscles might be more critical and effective delivery sites, as these are often the earliest sites of pathology.⁵⁴
- **Improper NTF Selection:** Brain-Derived Neurotrophic Factor (BDNF) was widely used in past trials. However, recent studies suggest that other NTFs, such as Glial Cell Line-Derived Neurotrophic Factor (GDNF) and Neurotrophin-4 (NT-4), might be more suitable candidates for ALS therapy.⁵⁴
- **Improper Timing of Treatment:** Most clinical trials initiated NTF administration at or after the onset of overt ALS symptoms. However, it is now recognized that significant pathological alterations in skeletal muscles and NMJs occur very early in the disease course, often before clinical symptoms manifest.⁵⁴

New insights into ALS pathology and NTF biology are informing future strategies. Studies have revealed intrinsic differences in NTF expression patterns between extraocular muscles (EOMs), which are notably spared in ALS, and limb muscles, which are severely affected.⁵⁴ This observation suggests that NTFs play a role in the remarkable resistance of EOMs to the disease, providing valuable clues for therapeutic development.

Neurotrophic factors currently show emerging potential for disease modification, but this potential is contingent upon future therapeutic strategies successfully addressing the identified critical issues of administration site, specific NTF selection, and, crucially, the timing of intervention. This may necessitate very early, even presymptomatic, administration to maximize therapeutic benefit.⁵⁴

A significant understanding emerging from the diverse therapeutic approaches is the recognition that ALS pathology is not driven by a single defect but rather by a complex cascade of interconnected issues, including neuroinflammation, oxidative stress, mitochondrial dysfunction, and protein aggregation. This understanding leads to the conclusion that effective treatments are likely to be those that can address several of these pathological pathways simultaneously, either through a single pleiotropic agent or via combination therapies. This represents a strategic shift beyond a simplistic "fix one problem" approach.

Furthermore, the recognition that pathological changes, such as those in neuromuscular junctions, glial activation patterns, or even genetic predispositions, occur very early in the disease course, often before clinical symptoms are apparent, highlights the critical need for early diagnosis and intervention. This necessitates a strong emphasis on the development and validation of robust biomarkers. For example, Qalsody's approval was partly based on reductions in neurofilament light chain (NfL), a biomarker for neurodegeneration.⁸ Initiatives like the "Access for All in ALS Consortium" (ALL ALS) are actively collecting clinical and biomarker data from asymptomatic individuals at risk, aiming to enable earlier intervention.⁴⁷ This emphasis on early detection and treatment, guided by reliable biomarkers, is crucial for maximizing the potential for disease modification or even reversal, as significant irreversible damage may have already occurred by the time clinical symptoms become evident.

V. Comparative Analysis and Potential for Disease Reversal

A. Defining "Disease Reversal" in ALS

In the context of Amyotrophic Lateral Sclerosis, a rapidly progressive and currently incurable neurodegenerative disease, the term "disease reversal" represents a highly ambitious and challenging therapeutic objective. Its interpretation exists along a spectrum of outcomes:

- **Symptomatic Relief:** This refers to alleviating the symptoms of the disease (e.g., muscle cramps, spasticity, pain) without fundamentally altering the underlying disease course. Riluzole, for instance, initially provided modest symptomatic and survival benefits without true reversal. Some neuromodulation techniques also primarily fall into this category.
- **Slowing Disease Progression:** This involves reducing the rate at which functional decline occurs. Edaravone and some emerging small molecules demonstrate this effect, extending the period of functional independence but not halting the disease entirely.
- **Disease Stabilization:** This signifies halting or arresting the progression of the disease, preventing any further functional loss. This is a significant achievement in a progressive neurodegenerative disorder.
- **Functional Preservation:** This involves maintaining existing neurological function, effectively preventing the expected decline that would otherwise occur.
- **Functional Improvement/Recovery:** This is the closest to true "disease reversal," where lost neurological function is regained, even if partially. This represents a restoration of capabilities that were previously diminished or lost.
- **Biomarker Normalization:** This involves reversing pathological changes in biological markers (e.g., protein levels, inflammatory markers) that may precede or correlate with clinical improvement. While not a direct measure of functional recovery, it indicates a positive impact on underlying disease processes.

It is important to acknowledge the rare, yet documented, instances of "ALS reversals".⁶ These isolated cases, while anecdotal from a clinical trial perspective, provide crucial biological proof-of-concept that some form of recovery or arrest of progression

is possible, thereby fueling ongoing research into the underlying protective mechanisms that might be leveraged therapeutically.

B. Ranking by Potential for Disease Reversal

This ranking assesses the various treatments based on the strength of evidence for their ability to impact the disease course beyond mere symptomatic relief, prioritizing functional preservation, improvement, or halting progression.

Highest Potential (Evidence of Functional Improvement/Stabilization in Humans)

- **Qalsody (Tofersen):** This FDA-approved antisense oligonucleotide (ASO) for *SOD1*-ALS stands out as demonstrating the most compelling evidence for functional recovery or reversal in human ALS patients. Real-world data indicate "meaningful preservation of function and suggestions of sustained improvement in neurologic function in some patients".¹⁷ Furthermore, it has shown "potential not only to stabilize the disease but also to restore lost function".¹⁸ This is a critical distinction from merely slowing decline, as it points to actual regaining of capabilities. The efficacy observed, while specific to *SOD1*-ALS, represents a significant breakthrough in the pursuit of disease reversal.

Moderate Potential (Disease Modification/Significant Slowing of Progression)

- **CRISPR/Cas9-Mediated Gene Correction:** While still in preclinical stages for direct human application in ALS, CRISPR/Cas9 demonstrates profound mechanistic impact. Studies in iPSC and mouse models show not just a delay in disease onset and increased survival, but also a *reversal* of pathological phenotypes, such as increased motor neuron proportion and decreased cell death.¹ This direct targeting of the genetic root cause suggests a fundamental impact on the disease process, placing it high in terms of potential, awaiting translation to human clinical trials.
- **CNM-Au8 (Oral Suspension of Gold Nanocrystals):** Phase 2 clinical trial data for CNM-Au8 has indicated a significant reduction in ALS disease progression events, including death and the need for ventilatory or feeding support. The trial also reported improved quality of life for treated participants.⁴³ This suggests a substantial positive impact on the overall disease trajectory, moving beyond simply slowing the rate of decline to significantly altering critical disease milestones.
- **CB2 Receptor Agonists (e.g., AM-1241):** Strong preclinical evidence supports the potential of CB2 receptor agonists. In mouse models of ALS, these compounds have demonstrated delayed symptom onset, slowed disease progression, and notably prolonged survival, with AM-1241 increasing the survival interval by up to 56%.³² These findings suggest a direct impact on the neurodegenerative process and functional preservation, indicating moderate potential, pending human clinical validation.
- **Palmitoylethanolamide (PEA):** Human studies with PEA have shown symptomatic benefits, including an improved clinical picture and enhanced pulmonary function.²⁸ Preclinical evidence further suggests that PEA may act as a disease-modifying agent in the early stages of neurocognitive disorders by reducing neuroinflammation and oxidative stress.²⁵ While current human ALS data does not explicitly show "reversal," its impact on a key functional measure (FVC) and its broad neuroprotective and anti-inflammatory mechanisms point to a significant disease-modifying potential.
- **Immunomodulatory Cell Therapies (Mesenchymal Stem Cells (MSCs), T Regulatory (Treg) Cells):** These cell-based therapies aim to modulate neuroinflammation, provide neuroprotection through trophic factors, reduce oxidative stress, and potentially contribute to cell replacement.⁴ Their potential to create a nurturing, neuroprotective microenvironment and, in some cases, differentiate into new cells, suggests a fundamental impact on disease progression. However, clear human efficacy data demonstrating widespread functional recovery or reversal is still emerging from ongoing early-phase trials.

Emerging/Symptomatic Management Potential (Early-Stage Evidence, Primarily Symptomatic or Indirect Impact)

- **General Stem Cell Therapies (e.g., Neural Stem Cells for Motor Neuron Replacement):** The initial concept of directly replacing lost motor neurons with stem cells has proven challenging due to difficulties in cellular integration and survival within the hostile diseased microenvironment.⁴ While promising in theory, the practical hurdles mean that direct cell replacement for widespread functional recovery remains a long-term, aspirational goal. The current focus has shifted towards stem cells fulfilling a supportive role, which, while beneficial, offers a less direct path to reversal.
- **Neuromodulation (Transcranial Magnetic Stimulation (TMS), Spinal Direct Current Stimulation (sDCS), Brain-Computer Interfaces (BCI)):** These approaches primarily focus on modulating neuronal excitability, improving communication, and enhancing the quality of life for patients.⁴⁴ While a mouse study showed increased survival with non-invasive neuromodulation⁵¹, the primary demonstrated human benefits from these techniques are related to symptomatic relief and functional assistance (e.g., BCIs for communication) rather than reversing the underlying neurodegeneration.
- **Neurotrophic Factors (Revisited):** Despite their biological relevance, past clinical trials involving neurotrophic factors have largely failed.⁵⁴ This highlights significant challenges related to optimal administration sites, appropriate factor selection, and, critically, the timing of intervention. While new insights suggest potential if these issues are meticulously addressed (e.g., very early, presymptomatic intervention), their current potential for disease reversal remains largely theoretical and highly speculative.

Table 2: Comparative Potential for ALS Disease Reversal

| Treatment Category | Specific Treatment/Approach | Primary Mechanism(s) of Action | Potential for Disease Reversal | Current Evidence Level (Human) |
|-------------------------------|---------------------------------------|--|--------------------------------|---|
| Genetic Therapies | Qalsody (Tofersen) | Reduces toxic SOD1 protein production (ASO) | Highest Potential | FDA-approved, Real-world data: Functional improvement/stabilization ¹⁷ |
| | CRISPR/Cas9-Mediated Gene Correction | Direct gene editing to correct mutations | Moderate Potential | Preclinical: Reversal of pathological phenotypes, increased survival in models ¹ |
| Cannabinoid System Modulators | CB2 Receptor Agonists (e.g., AM-1241) | Immunomodulation, neuroprotection, anti-inflammation | Moderate Potential | Preclinical: Delayed onset, prolonged survival in models ³² |
| | Palmitoylethanolamide (PEA) | Anti-inflammatory, neuroprotective, immunoregulatory | Moderate Potential | Human: Symptomatic benefits, improved pulmonary function; Preclinical: |

| | | | | |
|--|---|--|---|---|
| | | | | Disease-modifying in early stages ²⁵ |
| Cell-Based Therapies | Immunomodulatory Cell Therapies (MSCs, Treg Cells) | Reduce neuroinflammation, neuroprotection, oxidative stress reduction | Moderate Potential | Early Clinical (Phase 1/2): Mechanisms support slowing neurodegeneration ⁴ |
| Novel Small Molecules & Biologics | CNM-Au8 | Restores neuronal energy, reduces oxidative stress, improves protein homeostasis | Moderate Potential | Phase 2: Significant reduction in disease progression events, improved QoL ⁴³ |
| | Ibudilast (MN-166) | Neuroprotective, anti-inflammatory (PDE inhibitor) | Moderate Potential | Phase 2b/3: Ongoing evaluation for slowing progression ⁴² |
| Emerging/Symptomatic Management | General Stem Cell Therapies (e.g., NSCs for MN replacement) | Cell replacement (conceptually), supportive microenvironment | Emerging/Symptomatic Management Potential | Early Clinical: Challenges in direct replacement; focus on supportive roles ⁴ |
| | Neuromodulation (TMS, sDCS, BCI) | Modulates neuronal excitability, improves communication | Emerging/Symptomatic Management Potential | Human: Symptomatic management, functional assistance; Preclinical: Increased survival in models ⁴⁴ |
| | Neurotrophic Factors (Revisited) | Promote neuronal survival and maintenance | Emerging/Symptomatic Management Potential | Past Clinical Trials: Failures due to delivery, selection, timing; New insights for future strategies ⁵⁴ |

Value of Table 2: This table provides a concise, at-a-glance comparison of the various therapeutic approaches discussed. It systematically categorizes treatments by their primary mechanism, summarizes their potential for disease reversal based on the available evidence, and clearly indicates their current stage of development. This structured presentation allows for rapid assimilation of complex information, facilitating a comparative understanding of the landscape of ALS therapies and their respective promise. It highlights the varying degrees of evidence, from preclinical models to FDA-approved human data, offering a clear perspective on which treatments are closest to achieving meaningful disease modification or reversal.

Works cited

1. CRISPR/Cas9-Mediated Gene Correction to Understand ALS - MDPI, accessed July 18, 2025, <https://www.mdpi.com/1422-0067/21/11/3801>
2. Current perspectives on neuromodulation in ALS patients: A systematic review and meta-analysis | PLOS One, accessed July 18, 2025, <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300671>
3. Multilayered neuroprotection by cannabinoids in neurodegenerative ..., accessed July 18, 2025, <https://www.explorationpub.com/Journals/ent/Article/100498>

4. Stem cell treatments for amyotrophic lateral sclerosis (ALS): A critical overview of early phase trials - PubMed Central, accessed July 18, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6697143/>
5. Heterogeneity of Neuroinflammatory Responses in Amyotrophic ..., accessed July 18, 2025, <https://www.mdpi.com/1422-0067/21/21/7923>
6. ALS Cure 2025: Does it Exist? - DVC Stem, accessed July 18, 2025, <https://www.dvcstem.com/post/als-cure>
7. Treatments and Therapies | ALS Network, accessed July 18, 2025, <https://alsnetwork.org/understanding-als/treatments-and-therapies/>
8. Riluzole, Edaravone, and Tofersen: The Approved Drugs for ALS Progression, accessed July 18, 2025, <https://www.als.net/news/approved-drugs-for-als-progression/>
9. Amyotrophic lateral sclerosis: a critical review of riluzole treatment, accessed July 18, 2025, <https://www.actaneurologica.com/index.php/anc/article/view/1634>
10. Clinical trials for neuroprotection in ALS - PubMed, accessed July 18, 2025, <https://pubmed.ncbi.nlm.nih.gov/20406180/>
11. Therapies Targeting ALS-Linked Genetic Mutations | The ALS Association, accessed July 18, 2025, <https://www.als.org/research/als-research-topics/genetics/therapies-targeting-als-linked-genetic>
12. Current Challenges in Elucidating ALS Disease Mechanisms and Therapeutic Advances, accessed July 18, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12110534/>
13. Cell and gene therapy for amyotrophic lateral sclerosis - PubMed, accessed July 18, 2025, <https://pubmed.ncbi.nlm.nih.gov/39341656/>
14. Dual role of microglia in health and disease: pushing the ... - Frontiers, accessed July 18, 2025, <https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2015.00051/full>
15. Palmitoylethanolamide Modulation of Microglia Activation: Characterization of Mechanisms of Action and Implication for Its Neuroprotective Effects - MDPI, accessed July 18, 2025, <https://www.mdpi.com/1422-0067/22/6/3054>
16. Medications for Treating ALS - The ALS Association, accessed July 18, 2025, <https://www.als.org/navigating-als/living-with-als/medications>
17. New Qalsody Results Bring Hope for Recovery of Lost Function and More Time, accessed July 18, 2025, <https://www.als.org/blog/new-qalsody-results-bring-hope-recovery-lost-function-and-more-time>
18. Study Demonstrates Sustained Stabilization and Functional Recovery in SOD1-ALS Patients Treated with Qalsody (Tofersen) | The ALS Association, accessed July 18, 2025, <https://www.als.org/stories-news/study-demonstrates-sustained-stabilization-and-functional-recovery-sod1-als-patients>
19. Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries—A Systematic Review - MDPI, accessed July 18, 2025,

- <https://www.mdpi.com/1422-0067/21/24/9526>
20. Chronic palmitoylethanolamide administration via slow-release subcutaneous pellets promotes neuroprotection and mitigates neuroinflammation in the Tg2576 mouse model of Alzheimer's disease - Frontiers, accessed July 18, 2025, <https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2025.1571428/full>
 21. Palmitoylethanolamide, an endogenous fatty acid amide, and its pleiotropic health benefits: A narrative review - The Journal of Biomedical Research, accessed July 18, 2025, <http://www.jbr-pub.org.cn/article/doi/10.7555/JBR.38.20240053>
 22. OBM Neurobiology | Palmitoylethanolamide for Neurological ... - lidsen, accessed July 18, 2025, <https://www.lidsen.com/journals/neurobiology/neurobiology-04-04-076>
 23. Neuroprotective and Immunomodulatory Action of the Endocannabinoid System under Neuroinflammation - MDPI, accessed July 18, 2025, <https://www.mdpi.com/1422-0067/22/11/5431>
 24. Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation - MDPI, accessed July 18, 2025, <https://www.mdpi.com/2227-9059/13/6/1271>
 25. Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence - Frontiers, accessed July 18, 2025, <https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.1038122/full>
 26. PPARs and Energy Metabolism Adaptation during Neurogenesis ..., accessed July 18, 2025, <https://www.mdpi.com/1422-0067/19/7/1869>
 27. Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications, accessed July 18, 2025, <https://innovationscns.com/palmitoylethanolamide-treatment-long-covid-19/>
 28. Amyotrophic lateral sclerosis treatment with ultramicrosized palmitoylethanolamide: a case report - PubMed, accessed July 18, 2025, <https://pubmed.ncbi.nlm.nih.gov/22998138/>
 29. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy, accessed July 18, 2025, <https://pubmed.ncbi.nlm.nih.gov/26929355/>
 30. PALMITOYLETHANOLAMIDE (PEA): Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - WebMD, accessed July 18, 2025, <https://www.webmd.com/vitamins/ai/ingredientmono-1596/palmitoylethanolamide-pea>
 31. Palmitoylethanolamide and Related ALIAmides: Prohomeostatic Lipid Compounds for Animal Health and Wellbeing - MDPI, accessed July 18, 2025, <https://www.mdpi.com/2306-7381/7/2/78>
 32. Emerging role of the cannabinoid receptor CB2 in immune ..., accessed July 18, 2025, <https://www.cambridge.org/core/journals/expert-reviews-in-molecular-medicine/article/emerging-role-of-the-cannabinoid-receptor-cb2-in-immune-regulation-t>

[herapeutic-prospects-for-neuroinflammation/F05306C0BDCE1C7D9A956B5A76DCAC7F](https://www.mdpi.com/1422-0067/22/17/9472)

33. The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases, accessed July 18, 2025, <https://www.mdpi.com/1422-0067/22/17/9472>
34. Phytocannabinoids, Neuroprotection And The Blood-Brain Barrier, accessed July 18, 2025, <https://eprints.nottingham.ac.uk/65309/1/Phytocannabinoids%2C%20Neuroprotection%20and%20the%20BBB%20resubmission%20pdf.pdf>
35. Cannabis, a Miracle Drug with Polyvalent Therapeutic Utility ..., accessed July 18, 2025, <https://karger.com/mca/article-abstract/4/1/43/188934>
36. Cannabinoid analogs in the treatment of pain, accessed July 18, 2025, https://analesranf.com/wp-content/uploads/2016/82_02/8202_07.pdf
37. Therapeutic Potential of Cannabinoids in Neurodegenerative Disord ..., accessed July 18, 2025, <https://www.ingentaconnect.com/content/ben/cpd/2014/00000020/00000013/art00013>
38. Can Physical Activity Support the Endocannabinoid System in the Preventive and Therapeutic Approach to Neurological Disorders? - MDPI, accessed July 18, 2025, <https://www.mdpi.com/1422-0067/21/12/4221>
39. Stem Cells: ALS Treatment Breakthrough (2025), accessed July 18, 2025, <https://www.dvcstem.com/post/stem-cells-als>
40. Study Details | Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis (STEMALS), accessed July 18, 2025, <https://clinicaltrials.gov/study/NCT06344260>
41. Texas A&M Inventor Turns Breakthrough Cell Therapy Into Hope for Patients with ALS and other Devastating Diseases - TAMUS System News, accessed July 18, 2025, <https://news.tamus.edu/texas-am-inventor-turns-breakthrough-cell-therapy-into-hope-for-patients-with-als-and-other-devastating-diseases/>
42. After myriad failures, a new wave of ALS drugs approaches | PharmaVoice, accessed July 18, 2025, <https://www.pharmavoices.com/news/als-drug-approaches-coya-amylx/751540/>
43. RESCUE-ALS Trial Results: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in ALS - MDA Conference, accessed July 18, 2025, <https://www.mdaconference.org/abstract-library/rescue-als-trial-results-a-phase-2-randomized-double-blind-placebo-controlled-study-of-cnm-au8-to-slow-disease-progression-in-als/>
44. Open ALS Clinical Trials - Johns Hopkins Medicine, accessed July 18, 2025, <https://www.hopkinsmedicine.org/neurology-neurosurgery/clinical-trials/als-clinical-trials/open-trials>
45. Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) (HIMALAYA) - ClinicalTrials.gov, accessed July 18, 2025, <https://clinicaltrials.gov/study/NCT05237284>
46. Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS (CARDINALS) - ClinicalTrials.gov, accessed July

- 18, 2025, <https://clinicaltrials.gov/study/NCT05349721>
47. Trial News & Events / 2024 - NEALS, accessed July 18, 2025, <https://neals.org/als-trials/trials-news-events/2024>
48. Study Details | MRG-001 in Patients With Amyotrophic Lateral Sclerosis | ClinicalTrials.gov, accessed July 18, 2025, <https://clinicaltrials.gov/study/NCT06315608?cond=%22Amyotrophic%20Lateral%20Sclerosis%22&aggFilters=status:not%20rec&rank=9>
49. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights | Journal of Neurology, Neurosurgery & Psychiatry, accessed July 18, 2025, <https://jnnp.bmj.com/content/84/10/1161>
50. Study Details | Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis | ClinicalTrials.gov, accessed July 18, 2025, <https://clinicaltrials.gov/study/NCT00833820>
51. Press releases - PathMaker Neurosystems, accessed July 18, 2025, <https://pmneuro.com/news/press-releases/>
52. Non-Invasive Transcutaneous Spinal DC Stimulation as a Neurorehabilitation ALS Therapy in Awake G93A Mice: The First Step to Clinical Translation - PubMed Central, accessed July 18, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9495504/>
53. What's the Latest on ALS Research and Clinical Trials? - Mass General Brigham, accessed July 18, 2025, <https://www.massgeneralbrigham.org/en/about/newsroom/articles/whats-the-latest-on-als-research-and-clinical-trials>
54. Unchanged Neurotrophic Factors and Their Receptors Correlate ..., accessed July 18, 2025, <https://iovs.arvojournals.org/article.aspx?articleid=2595000>
55. Study of ALS Reversals 4: LifeTime Exposures (StARLiTE) - ClinicalTrials.gov, accessed July 18, 2025, <https://clinicaltrials.gov/study/NCT03706391>
56. Record History | ver. 4: 2019-02-06 | NCT03464903 - ClinicalTrials.gov, accessed July 18, 2025, <https://www.clinicaltrials.gov/study/NCT03464903?tab=history&a=4>